Aptevo: 21% of Frontline AML Patients Reached Stem Cell Transplant on Mipletamig Triplet
APVO sits 18% above its 52-week low of $1.37 on light trading volume (0.1× avg).
Summary
Aptevo reported that 10 of 47 (21%) evaluable frontline AML patients on its mipletamig triplet advanced to stem cell transplant, versus 0.7% in the VIALE-A historical VEN+AZA arm. RAINIER dose optimization is expected to finish by year-end 2026, with FDA talks and a Phase 2 start targeted for H1 2027.
Key Events · Product Development and Regulatory · APVO
-
21% Transplant Rate on Mipletamig Triplet
Ten of 47 (21%) evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine proceeded to allogeneic stem cell transplant, including nine from the ongoing Phase 1b RAINIER trial and one from the prior dose expansion trial.
-
Favorable vs VIALE-A Historical Benchmark
In the pivotal Phase 3 VIALE-A trial, three of 286 patients (0.7%) on VEN+AZA alone underwent transplant, versus 21% here; the company notes cross-trial comparisons are limited by population, design and follow-up differences.
-
RAINIER Timeline and Next Regulatory Step
Aptevo expects to complete RAINIER dose optimization by year-end 2026 and discuss next steps with regulators in the first half of 2027, with a Phase 2 trial anticipated to start in that same window.
-
Context: Going Concern and Recent Financing
The data lands against previously disclosed going-concern doubt and a $4.5M August 2026 warrant inducement/PIPE that left heavy warrant overhang; clinical progress is the primary offset to that balance-sheet pressure.
Analysis · APVO · Life Sciences
Transplant conversion is a hard, clinically meaningful endpoint, and the triplet cleared it at a 21% rate: ten of 47 frontline AML patients treated with mipletamig plus venetoclax and azacitidine went on to allogeneic stem cell transplant, a potentially curative step. For context, 3 of 286 (0.7%) on VEN+AZA alone in the VIALE-A trial did so. Cross-trial comparisons are imperfect, but the gap supports the triplet's activity in patients unfit for intensive chemotherapy. On timing, RAINIER dose optimization is expected to wrap by year-end 2026, with an FDA interaction and Phase 2 start in the first half of 2027. Against a going-concern backdrop and a $4.5M August financing, clinical momentum is the main lever on the story; the next hard checkpoint is the RAINIER conclusion and regulatory feedback.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.37 to $28.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.